EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel [1,2,4]Triazolo[1,5- a ]pyrimidine Derivatives as Novel Potent S-Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer

Kaizhao Hu, Yongqiang Luo, Peipei Miao, Lidan Zhao, Bing Zhao iD, Xiao-Jing Shi iD, Hong-Min Liu

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Kaizhao Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Laboratory Animal Center, State Key Laboratory of Esophageal Cancer…. Hauptthemen laut MEDLINE: S-Phase Kinase-Associated Proteins, Pyrimidines, Antineoplastic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Skp1-CUL1-ROC1-F-box E3 ubiquitin ligases' main component S-phase kinase-associated protein 2 (Skp2) is responsible for specifically recognizing ubiquitination-modified substrates to be degraded such as p27 and p21 in the case of binding with adaptor protein Cks1. Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-a]pyrimidine-based small molecules targeting Skp2. Among them, E35 demonstrated excellent inhibitory activities against the binding of Skp2-Cks1. In addition, compound E35 significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. Mechanistically, compound E35 markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. Furthermore, compound E35 showed an obvious inhibitory effect on MGC-803 xenograft mice without obvious toxicity. All of these results suggest that compound E35 might be a valuable lead compound for antitumor agents targeting Skp2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

S-Phase Kinase-Associated ProteinsPyrimidinesAntineoplastic AgentsHumansAnimalsMiceCell Line, TumorStructure-Activity RelationshipDrug DiscoveryTriazolesMice, NudeProtein Kinase InhibitorsCDC2-CDC28 KinasesXenograft Model Antitumor AssaysMice, Inbred BALB CCell Proliferation

Substanzen

S-Phase Kinase-Associated ProteinsPyrimidinesAntineoplastic AgentsSKP2 protein, humanTriazolesProtein Kinase InhibitorsCDC2-CDC28 KinasesCKS1B protein, human

Autor:innen und Institutionen

  • Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Laboratory Animal Center, State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan Provin…
  • Key Laboratory of Technology of Drug Preparation (Zhengzhou University), Ministry of Education of China; Key Laboratory of Henan Province for Drug Quality and Evaluation; Institute of Pharmaceutical Sciences, Zhengzhou…

ORCID-Profile: Bing Zhao, Xiao-Jing Shi

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Hu, K., Luo, Y., Miao, P., Zhao, L., Zhao, B., Shi, X. J., & Liu, H. M. (2024). Discovery of Novel [1,2,4]Triazolo[1,5- a ]pyrimidine Derivatives as Novel Potent S-Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01283

Vancouver

Hu K, Luo Y, Miao P, Zhao L, Zhao B, Shi XJ, et al. Discovery of Novel [1,2,4]Triazolo[1,5- a ]pyrimidine Derivatives as Novel Potent S-Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01283

BibTeX
@article{Hu2024,
  author = {Hu, Kaizhao and Luo, Yongqiang and Miao, Peipei and Zhao, Lidan and Zhao, Bing and Shi, Xiao-Jing and Liu, Hong-Min},
  title = {Discovery of Novel [1,2,4]Triazolo[1,5- a ]pyrimidine Derivatives as Novel Potent S-Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01283}
}
Kostenlos starten →